By: S. Sutter
27 September 2010
Merck’s bid to further expand the label for its human papillomavirus vaccine Gardasil – this time for the prevention of anal cancer and anal dysplasia – will face FDA advisory committee scrutiny in November. The Vaccines and Related Biological Products Advisory Committee will meet on Nov. 17 to discuss the effectiveness of Gardasil vaccination of males and females to prevent anal dysplasia and anal cancer. Merck submitted the sBLA earlier this year but has not specified the date of submission, saying…
Leave a Reply